SOTIO Reveals Promising Preclinical Results for SOT109 and SOT106 in Solid Tumor Therapy

In the dynamic world of oncology, SOTIO Biotech, a clinical-stage biopharmaceutical entity under the PPF Group, has recently showcased preclinical findings on two of its pioneering antibody-drug conjugate (ADC) candidates, SOT109 and SOT106. These findings were unveiled at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Illinois. The promising data reveal significant anti-tumor potential and a favorable tolerability profile in diverse tumor models, positioning these ADCs as potential groundbreaking therapies for various solid tumors.

SOT109 is strategically developed to target CDH17, a promising antigen, particularly for gastrointestinal cancers such as colorectal cancer (CRC), which still presents high unmet needs. ADCs have struggled to achieve clinical success in CRC due to the absence of ideal target antigens. CDH17 stands out as a target antigen, being overexpressed in more than 90% of CRCs and also prevalent in other gastrointestinal malignancies. Its expression is mostly confined to the gastrointestinal tract in adults, thereby minimizing off-target toxicity. SOT109 incorporates a proprietary, highly internalizing, fully human antibody in conjunction with Synaffix B.V.’s leading-edge ADC platform. The antibody, target epitope, and the linker/payload design have been meticulously chosen to enhance efficacy and safety.

During the conference, SOTIO presented a poster on SOT109 that highlighted its significant attributes. The data underscored its strong anti-tumor activity and excellent tolerability across various preclinical models of colorectal cancer, reinforcing its potential as a best-in-class ADC for treating these cancers.

Meanwhile, SOT106 employs LigaChem Biosciences’ proven ConjuAll™ ADC platform for precise tumor-specific MMAE release. It targets LRRC15, a clinically validated target offering new precision treatment possibilities. SOTIO’s oral presentation on SOT106 emphasized its broad application in LRRC15-associated sarcomas and other solid tumors, marking it as a potentially leading ADC in its category. The presentation shed light on SOT106's novel approach and its capacity to address complex oncology needs.

Martin Steegmaier, Ph.D., Chief Scientific Officer at SOTIO, emphasized the importance of these findings, stating, "The data we presented at AACR this week highlights the strength of our next-generation ADCs by addressing areas of high unmet need in oncology. SOT109 continues to show excellent tolerability and strong anti-tumor activity across multiple preclinical models of colorectal cancer, while SOT106 offers a novel precision approach with broad applicability in LRRC15 sarcomas and other solid tumors. These findings mark important progress in our pipeline and reinforce our commitment to developing highly differentiated ADCs for difficult to treat solid tumors.”

SOTIO Biotech is on a mission to revolutionize cancer immunotherapies by converting innovative scientific research into tangible patient benefits. The company is building an advanced pipeline of mono- and bispecific solid tumor ADC programs at various preclinical stages. Additionally, SOTIO’s pipeline includes two clinical-stage programs: BOXR1030, a CAR-T cell therapy enhanced metabolically to target GPC3-expressing tumors, and SOT201, a next-generation PD-1-targeting immunocytokine. As a member of the PPF Group, SOTIO remains dedicated to advancing cancer treatment through innovation and science-driven solutions.